ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Patient Advocate and Migraine Expert Discuss Drug-Free Migraine Treatment Options with YourUpdateTV

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) --  For millions of Americans living with migraine disease, traditional prescription treatments often come with unwanted side effects and limited functionality. But drug-free treatment options are making it easier to manage migraine – without the debilitating side effects. Recently. Neurologist and Migraine Specialist, Dr. Aliya Frederick, along with patient advocate, Sarah Aaronion, participated in a nationwide satellite media tour to discuss the growing role of drug-free migraine treatment and the importance of patient advocacy.

Migraine patients often experience debilitating, systemic side effects from prescription drug treatments, including drowsiness, confusion, and difficulty functioning at school or work. For many, these side effects limit the ability to drive, engage in social activities, or maintain independence. In some cases, individuals are forced to choose between treating their migraine and remaining functional. Concerns about drug interactions with other health conditions further complicate care.

The Nerivio® REN wearable provides a clinically proven, drug-free solution for both acute and preventive treatment of migraine in adults and children aged 8 and older.

This FDA-cleared treatment provides relief without the systemic side effects associated with prescription medications; and has recently been cleared for use in patients as young as 8 years old. Worn on the upper arm and controlled by a smartphone app, the device uses Remote Electrical Neuromodulation (REN) to activate the brain’s natural pain regulation system, relieving migraine symptoms during an attack and, when used regularly, reducing the frequency and burden of future episodes.     

Clinical evidence supports early, preventive treatment for migraine. It’s important to have a variety of safe and effective treatment options– that are affordable, promote adherence and help prevent long-term complications like chronic migraine.

Insurance coverage for drug-free treatment options is expanding, but not yet universal. Patients and providers are working together to advocate for broader coverage, submitting efficacy data and success stories to insurers. Many patients have successfully pushed for their treatment to be included in health plans, contributing to positive momentum across the healthcare system.

For more information about drug-free migraine treatment options and tools for insurance advocacy, visit www.NerivioCovered.com

About Dr. Aliya Frederick
Dr. Aliya Frederick, MD, PhD, is an Assistant Professor of Pediatrics and Neurology based in San Diego, California. She specializes in treating migraine and headache disorders, primarily in children, adolescents and young adults, with a focus on providing innovative, patient-centered care to improve quality of life and health outcomes. Dr. Frederick is a strong advocate for expanding access to effective migraine therapies, including non-pharmacologic treatment options like the Nerivio REN wearable device, and works to eliminate barriers to care through clinical research and insurance advocacy.

About Sarah Aaronion
Sarah Aaronion is a 33-year-old IT professional from Georgetown, MA, who has been living with migraines for over 16 years. It was a constant part of her life that affected her physically, mentally, and emotionally. After struggling with prescription medications that caused debilitating, systemic side effects, she found relief with the Nerivio REN wearable, a drug-free, needle-free treatment that allows her to manage migraines without disrupting her daily life. Sarah is now an advocate for broader insurance coverage of migraine treatments, encouraging others to push for access to the care they need.

* YourUpdateTV is a property of D S Simon Media. The video included and release was part of a media tour that was produced by D S Simon Media on behalf of Nerivio®

Dante Muccigrosso
Director of Media Integration & Client Reporting
E: dantem@dssimon.com
C: 973.524.0104

A video accompanying this announcement is available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/1c6c0763-e3c9-4806-85c8-2d298932ba26


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  229.53
+0.42 (0.18%)
AAPL  278.78
-1.92 (-0.68%)
AMD  217.97
+1.99 (0.92%)
BAC  53.95
+0.07 (0.13%)
GOOG  322.09
+3.70 (1.16%)
META  673.42
+11.89 (1.80%)
MSFT  483.16
+2.32 (0.48%)
NVDA  182.41
-0.97 (-0.53%)
ORCL  217.58
+3.25 (1.52%)
TSLA  455.00
+0.47 (0.10%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.